TScan Therapeutics, Inc. (TCRX)
| Market Cap | 78.73M +23.1% |
| Revenue (ttm) | 10.33M +266.7% |
| Net Income | -129.77M |
| EPS | -1.00 |
| Shares Out | 60.10M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 936,707 |
| Open | 1.270 |
| Previous Close | 1.260 |
| Day's Range | 1.220 - 1.355 |
| 52-Week Range | 0.882 - 2.570 |
| Beta | 1.01 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+434.35%) |
| Earnings Date | May 8, 2026 |
About TCRX
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It ... [Read more]
Financial Performance
In 2025, TScan Therapeutics's revenue was $10.33 million, an increase of 266.65% compared to the previous year's $2.82 million. Losses were -$129.77 million, 1.78% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TCRX stock is "Strong Buy." The 12-month stock price target is $7.0, which is an increase of 434.35% from the latest price.
News
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...
TScan Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
The conference highlighted a differentiated TCR T cell therapy platform targeting post-transplant AML/MDS relapse, with phase I data showing >50% relapse reduction and long-lived responses. A pivotal trial launches mid-2024, with commercial launch expected in 2029 and strong profit margins projected. Additional HLA-targeted products and an in vivo solid tumor platform are in development.
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...
TScan Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Lead TCR T-cell therapy for heme malignancies shows strong phase I efficacy and safety, with pivotal trial launching in Q2 and commercial-ready manufacturing in place. Market expansion through additional HLA-targeted products could double the addressable patient population.
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Presented positive updated data from the ALLOHA ™ Phase 1 heme trial at 67 th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of Phase...
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
TScan Therapeutics Transcript: KOL Event
Updated data show TSC-101 delivers strong efficacy and safety in high-risk AML/MDS post-transplant patients, with a new commercial-ready process improving scalability and cost. The pivotal trial is set for Q2 next year, with plans to expand the addressable market through additional HLA-targeted products.
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
TScan Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Lead heme malignancy program shows 82% relapse-free rate and is moving to a pivotal trial in Q2 next year. Solid tumor efforts pivot to in vivo engineering, and autoimmunity research advances with new target discoveries. Cash runway now extends into the second half of 2027.
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHA ™ Phase 1 heme trial to be presented at the 67 th American Society of Hemato...
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
TScan Therapeutics Transcript: FDA Announcement
FDA agreed to additional high-dose patient data collection before pivotal trial launch in Q2 2026. A new manufacturing process improves efficiency and is expected to enhance efficacy. Strategic focus shifts to the HEME program, with solid tumor efforts moving to in vivo engineering.
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritiz...
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025 Highlights discovery of novel targets in T cell-driven autoimm...
TScan Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Lead heme malignancy program demonstrated a significant reduction in relapse rates, supporting a pivotal trial launch this year. Market expansion is underway through new HLA-targeted TCRs, while multiplex solid tumor and autoimmunity programs are advancing, with key data readouts expected by early next year.
TScan Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
TCR-T cell therapy programs show promising early results in reducing relapse rates for hematologic malignancies, with a pivotal trial launching this year and expansion to new HLA types underway. Multiplex TCR therapy for solid tumors is advancing, with key safety and efficacy data expected in Q1 next year.
TScan Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents...
TScan Therapeutics Transcript: Jefferies Global Healthcare Conference 2025
Two clinical programs are advancing: a heme malignancy therapy with strong early results and a solid tumor multiplex TCR approach. A pivotal heme trial launches in H2 2024, with key data updates for both programs expected by year-end.
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
WALTHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (...
TScan Therapeutics Transcript: BofA Securities 2025 Healthcare Conference
A sequential IL-17/IL-23 therapy aims to optimize psoriasis treatment, with key Phase I and II data expected over the next year. Strong funding supports clinical progress, and half-life benchmarks are set to enable less frequent dosing.
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second ha...
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...
TScan Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference
The company is advancing TCR-engineered T cell therapies for heme and solid tumors, with pivotal trials and first efficacy data expected in the next 12–18 months. Manufacturing and regulatory processes are optimized, and financial runway extends into Q1 2027.